What diagnostic workup and treatment plan should be pursued for a patient with chronic refractory urticaria (unresponsive to omalizumab and dupilumab), severe joint pain, leg and facial swelling, night sweats, low‑grade fever, and a persistent enlarged level II lymph node?

Urgent Lymphoma Workup Required – This is NOT Simple Refractory Urticaria

Your constellation of symptoms—persistent enlarged lymph node over 6+ months, B symptoms (night sweats, fever, fatigue), severe systemic inflammation unresponsive to multiple biologics, and joint pain with swelling—demands immediate hematologic/oncologic evaluation before any further urticaria treatment escalation. This presentation raises serious concern for underlying lymphoproliferative disorder or systemic disease masquerading as urticaria.

Critical Red Flags Present

Your case has multiple alarm features that distinguish it from typical chronic spontaneous urticaria (CSU):

• Persistent enlarged level II lymph node documented on two ultrasounds 2+ months apart
• Constitutional B symptoms: drenching night sweats (worsening), low-grade fevers (100-100.1°F), profound fatigue
• Treatment-refractory disease: Failed omalizumab (Xolair) AND dupilumab (Dupixent) AND prednisone
• Severe joint pain limiting ambulation, requiring hospitalization-level consideration
• Progressive systemic involvement: facial/extremity swelling, bruising with hives

Immediate Diagnostic Workup Required

Priority 1: Rule Out Malignancy/Systemic Disease

Lymph node evaluation:

• Excisional biopsy of the enlarged level II node (not fine needle aspiration—need architecture)
• CT chest/abdomen/pelvis with contrast
• Complete blood count with differential looking for lymphocytosis, atypical cells, cytopenias
• Peripheral blood flow cytometry if lymphocytosis present
• LDH, beta-2 microglobulin

Systemic inflammatory markers:

• ESR, CRP (should be markedly elevated given your symptoms)
• Comprehensive metabolic panel including liver/kidney function
• Serum protein electrophoresis, immunofixation

Priority 2: CSU-Specific Testing (per 2022 guidelines)

Only after malignancy excluded 1:

• Total IgE level (low levels suggest type IIb autoimmune CSU, predict omalizumab failure)
• Anti-thyroid peroxidase (IgG-anti-TPO) antibodies
• Ratio of anti-TPO to total IgE (high ratio = autoimmune CSU)
• Basophil activation test or histamine release assay if available (positive predicts omalizumab non-response)
• Antinuclear antibodies, complement levels (C3, C4)
• Tryptase level (rule out mast cell activation syndrome/mastocytosis) 2

Priority 3: Consider Alternative Diagnoses

Given treatment failure pattern:

• Skin biopsy of active lesion (urticarial vasculitis, dermatitis herpetiformis can mimic urticaria) 3
• Celiac panel if biopsy suggests dermatitis herpetiformis
• Cryoglobulins, hepatitis B/C serology
• Autoinflammatory syndrome workup if family history present

Why This Matters for Treatment

You have likely failed omalizumab because you have type IIb autoimmune CSU (low IgE, autoantibodies), which responds poorly to anti-IgE therapy 4, 5. The 2022 international urticaria guidelines specifically note that patients with low total IgE, elevated anti-TPO, and positive basophil tests are omalizumab non-responders 1.

Dupilumab failure is unusual and further suggests this is not straightforward CSU. Recent real-world data shows dupilumab achieves control in 69.7% of omalizumab-refractory CSU at 24 weeks, but response is significantly lower (40%) in true omalizumab non-responders versus partial responders (85%) 6.

Treatment Algorithm AFTER Malignancy Excluded

If Confirmed Autoimmune (Type IIb) CSU:

Step 1: Cyclosporine (guideline-recommended third-line) 1

• Start 2.5-5 mg/kg/day divided twice daily
• Monitor BP and renal function (BUN/creatinine) every 6 weeks
• Target lowest effective dose
• Real-world data shows complete resolution in 80% of omalizumab-refractory cases 7
• Risks: hypertension, renal dysfunction, hirsutism, gum hypertrophy—but reversible with discontinuation

Step 2: Consider Mast Cell Stabilization 2

• Oral cromolyn 200mg four times daily (before meals and bedtime)
• Takes 4+ weeks to work
• Add leukotriene receptor antagonist (montelukast 10mg daily)
• Continue high-dose H1-antihistamines (up to 4x standard dose) 1

If Mast Cell Activation Syndrome Confirmed:

Based on elevated tryptase, extensive mediator symptoms 2:

• Cromolyn as above
• Multiple H1/H2 antihistamine combinations
• Leukotriene modifiers
• Consider aspirin therapy (in controlled setting—risk of triggering degranulation)
• Avoid known triggers

Emerging Options (If Above Fail):

• Remibrutinib (BTK inhibitor)—recently approved for CSU 5
• Anti-KIT antibodies (in development) 5
• Cytoreductive therapy if clonal mast cell disorder confirmed (midostaurin, cladribine) 2

Critical Pitfalls to Avoid

1. Do NOT continue escalating urticaria treatments without lymph node biopsy—your persistent adenopathy with B symptoms is lymphoma until proven otherwise

2. Do NOT assume this is CSU just because you have hives—dermatitis herpetiformis, urticarial vasculitis, and paraneoplastic syndromes can all present similarly 3

3. Do NOT use long-term systemic corticosteroids—they mask underlying disease and have severe adverse effects without addressing root cause 2

4. Do NOT delay workup—you have had progressive symptoms for 6+ months with documented structural abnormality (lymph node) and constitutional symptoms

Bottom Line

Stop treating this as refractory urticaria and start treating it as "systemic disease with urticarial features" until proven otherwise. The combination of persistent lymphadenopathy, B symptoms, and failure of multiple biologics is not consistent with typical CSU. You need hematology/oncology evaluation within 1-2 weeks, not another urticaria medication trial. If malignancy is excluded and autoimmune CSU confirmed, cyclosporine is your next evidence-based step per 2022 international guidelines 1.